Serologic responses to pneumocystis proteins in HIV patients with and without pneumocystis jirovecii pneumonia

Journal of Acquired Immune Deficiency Syndromes

Volumn 57, Issue 3, 2011, Pages 190-196

  Gingo, Matthew R ^a   Lucht, Lorrie ^a   Daly, Kieran R ^b   Djawe, Kpandja ^b   Palella, Frank J ^c   Abraham, Alison G ^d   Bream, Jay H ^d   Witt, Mallory D ^e   Kingsley, Lawrence A ^f   Norris, Karen A ^a   Walzer, Peter D ^b,g   Morris, Alison ^a,h  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h NONE   (United States)

Author keywords

AIDS; HIV; Pneumocystis; serology

Indexed keywords

CD4 ANTIGEN; IMMUNOGLOBULIN G;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELL COUNT; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PARTICIPANT OBSERVATION; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SEROLOGY; SURFACE PROPERTY;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBODIES, FUNGAL; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FUNGAL PROTEINS; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; RISK FACTORS; SERINE ENDOPEPTIDASES;

EID: 79959688565     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182167516     Document Type: Article

References (39)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860. (Pubitemid 28135961)
2. Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004;350:2487-2498.
3. Sepkowitz KA. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis. 2002;34: 1098-1107. (Pubitemid 34289683)
4. Harigai M, Koike R, Miyasaka N. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med. 2007;357:1874-1876. (Pubitemid 350044826)
5. Imaizumi K, Sugishita M, Usui M, et al. Pulmonary infectious complications associated with anti-TNF-alpha therapy (infliximab) for rheumatoid arthritis. Intern Med. 2006;45:685-688. (Pubitemid 43905483)
6. Kalyoncu U, Karadag O, Akdogan A, et al. Pneumocystis carinii pneumonia in a rheumatoid arthritis patient treated with adalimumab. Scand J Infect Dis. 2007;39:475-478. (Pubitemid 46705764)
7. Lahiff C, Khiaron OB, Nolan N, et al. Pneumocystis carinii pneumonia in a patient on etanercept for psoriatic arthritis. Ir J Med Sci. 2007;176: 309-311. (Pubitemid 350182773)
8. Mori S, Imamura F, Kiyofuji C, et al. Pneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis as a complication of treatment with infliximab, anti-tumor necrosis factor alpha neutralizing antibody. Mod Rheumatol. 2006;16:58-62.
9. Mansharamani NG, Balachandran D, Vernovsky I, et al. Peripheral blood CD4 + T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest. 2000;118: 712-720.
10. Phair J, Munoz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study group. N Engl J Med. 1990;322: 161-165. (Pubitemid 20036389)
11. Roths JB, Sidman CL. Single and combined humoral and cell-mediated immunotherapy of Pneumocystis carinii pneumonia in immunodeficient scid mice. Infect Immun. 1993;61:1641-1649. (Pubitemid 23145856)
12. Daly KR, Fichtenbaum CJ, Tanaka R, et al. Serologic responses to epitopes of the major surface glycoprotein of Pneumocystis jiroveci differ in human immunodeficiency virus-infected and uninfected persons. J Infect Dis. 2002;186:644-651. (Pubitemid 34925536)
13. Bishop LR, Kovacs JA. Quantitation of anti-Pneumocystis jiroveci antibodies in healthy persons and immunocompromised patients. J Infect Dis. 2003;187:1844-1848. (Pubitemid 36724482)
14. Daly KR, Koch J, Levin L, et al. Enzyme-linked immunosorbent assay and serologic responses to Pneumocystis jiroveci. Emerg Infect Dis. 2004;10: 848-854. (Pubitemid 38552752)
15. Garbe TR, Stringer JR. Molecular characterization of clustered variants of genes encoding major surface antigens of human Pneumocystis carinii. Infect Immun. 1994;62:3092-3101. (Pubitemid 24232087)
16. Gigliotti F, Haidaris CG, Wright TW, et al. Passive intranasal monoclonal antibody prophylaxis against murine Pneumocystis carinii pneumonia. Infect Immun. 2002;70:1069-1074. (Pubitemid 34163375)
17. Kling HM, Shipley TW, Patil S, et al. Pneumocystis colonization in immunocompetent and simian immunodeficiency virus-infected cynomolgus macaques. J Infect Dis. 2009;199:89-96.
18. Kutty G, Kovacs JA. A single-copy gene encodes KEX1, a serine endoprotease of Pneumocystis jiroveci. Infect Immun. 2003;71:571-574. (Pubitemid 36026068)
19. Mei Q, Turner RE, Sorial V, et al. Characterization of major surface glycoprotein genes of human Pneumocystis carinii and high-level expression of a conserved region. Infect Immun. 1998;66:4268-4273. (Pubitemid 28402701)
20. Wells J, Haidaris CG, Wright TW, et al. Active immunization against Pneumocystis carinii with a recombinant P. carinii antigen. Infect Immun. 2006;74:2446-2448.
21. Zheng M, Ramsay AJ, Robichaux MB, et al. CD4+ T cell-independent DNAvaccination against opportunistic infections. J Clin Invest. 2005;115: 3536-3544. (Pubitemid 43121841)
22. Zheng M, Shellito JE, Marrero L, et al. CD4+ T cell-independent vaccination against Pneumocystis carinii in mice. J Clin Invest. 2001;108: 1469-1474. (Pubitemid 33091984)
23. Stringer JR. Antigenic variation in Pneumocystis. J Eukaryot Microbiol. 2007;54:8-13. (Pubitemid 46188268)
24. Daly KR, Huang L, Morris A, et al. Antibody response to Pneumocystis jirovecii major surface glycoprotein. Emerg Infect Dis. 2006;12: 1231-1237.
25. Daly KR, Koch JV, Shire NJ, et al. Human immunodeficiency virusinfected patients with prior Pneumocystis pneumonia exhibit increased serologic reactivity to several major surface glycoprotein clones. Clin Vaccine Immunol. 2006;13:1071-1078. (Pubitemid 44622532)
26. Walzer PD, Djawe K, Levin L, et al. Long-term serologic responses to the Pneumocystis jirovecii major surface glycoprotein in HIV-positive individuals with and without P. jirovecii infection. J Infect Dis. 2009;199: 1335-1344.
27. Lee LH, Gigliotti F, Wright TW, et al. Molecular characterization of KEX1, a kexin-like protease in mouse Pneumocystis carinii. Gene. 2000; 242:141-150. (Pubitemid 30064499)
28. Russian DA, Andrawis-Sorial V, Goheen MP, et al. Characterization of a multicopy family of genes encoding a surface-expressed serine endoprotease in rat Pneumocystis carinii. Proc Assoc Am Physicians. 1999;111:347-356. (Pubitemid 29331467)
29. Kling HM, Shipley TW, Patil SP, et al. Relationship of Pneumocystis jiroveci humoral immunity to prevention of colonization and chronic obstructive pulmonary disease in a primate model of HIV infection. Infect Immun. 2010;78:4320-4330.
30. Kaslow RA, Ostrow DG, Detels R, et al. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol. 1987;126:310-318. (Pubitemid 17102758)
31. Morris A, Netravali M, Kling HM, et al. Relationship of Pneumocystis antibody response to severity of chronic obstructive pulmonary disease. Clin Infect Dis. 2008;47:e64-e68.
32. Kristoff J, Morris A, Tipirneni R, et al. Health care worker occupation is associated with Pneumocystis KEX1 antibody responses. Am J Respir Crit Care Med. 2009;179:A5539.
33. Djawe K, Huang L, Daly KR, et al. Serum antibody levels to the Pneumocystis jirovecii major surface glycoprotein in the diagnosis of P. jirovecii pneumonia in HIV+ patients. PLoS One. 2010;5:e14259.
34. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30(suppl 1):S5-S14.
35. Kaplan JE, Hanson DL, Navin TR, et al. Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virusinfected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis. J Infect Dis. 1998;178:1126-1132. (Pubitemid 28452208)
36. Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58(RR-4):1-207.
37. Helweg-Larsen J, Benfield TL, Eugen-Olsen J, et al. Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia. Lancet. 1999;354:1347-1351. (Pubitemid 29481631)
38. Iliades P, Meshnick SR, Macreadie IG. Mutations in the Pneumocystis jirovecii DHPS gene confer cross-resistance to sulfa drugs. Antimicrob Agents Chemother. 2005;49:741-748. (Pubitemid 40175688)
39. Kazanjian P, Armstrong W, Hossler PA, et al. Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients. J Infect Dis. 2000;182:551-557. (Pubitemid 30651053)